Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples